Alto Neuroscience (ANRO) Net Income towards Common Stockholders Growth (1y) (2024 - 2026)
Alto Neuroscience (ANRO) Net Income towards Common Stockholders Growth (1y) (2024 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Alto Neuroscience |
643.06 Mn |
379.30 Mn |
- |
-80.81% |
| Date | Value |
|---|
| Mar 31, 2026 |
-80.81% |
| Dec 31, 2025 |
-5.75% |
| Sep 30, 2025 |
15.93% |
| Jun 30, 2025 |
-10.07% |
| Mar 31, 2025 |
-9.66% |
| Dec 31, 2024 |
-33.49% |
| Sep 30, 2024 |
-78.66% |
| Jun 30, 2024 |
-82.47% |
| Mar 31, 2024 |
-80.59% |
